Corrigendum to “Anticancer activity of galactoxyloglucan polysaccharide-conjugated doxorubicin nanoparticles: Mechanistic insights and interactome analysis” [Eur. J. Pharm. Biopharm. 93 (2015) 183–195]

•Doxorubicin-associated toxicity could be overcome by conjugating with nanoparticles.•PST-Dox exhibited superior anticancer activity, sparing normal.•Interactome analysis revealed that PST-Dox inhibited tyrosine kinase oncogenic signaling.•Several promising and unique gene targets factored in the PST-Dox action.